Blueprint Medicines Corp. Forecast, price target & analysts
Blueprint Medicines Corp. Target price 2025 - Analyst rating & recommendation
Blueprint Medicines Corp. Classifications & Recommendation:
Blueprint Medicines Corp. Price Target
| Target Price | $131.58 |
| Price | $128.11 |
| Potential |
2.71%
register free of charge
|
| Number of Estimates | 18 |
|
18 Analysts have issued a price target Blueprint Medicines Corp. 2026 .
The average Blueprint Medicines Corp. target price is $131.58.
This is
2.71%
register free of charge
$141.75
10.65%
register free of charge
$130.29
1.70%
register free of charge
|
|
| A rating was issued by 27 analysts: 20 Analysts recommend Blueprint Medicines Corp. to buy, 6 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Blueprint Medicines Corp. stock has an average upside potential 2026 of
2.71%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 508.82 | 735.04 |
| 104.03% | 44.46% | |
| EBITDA Margin | -38.47% | -11.31% |
| 79.79% | 70.60% | |
| Net Margin | -13.19% | -7.97% |
| 93.51% | 39.55% |
23 Analysts have issued a sales forecast Blueprint Medicines Corp. 2025 . The average Blueprint Medicines Corp. sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an Blueprint Medicines Corp. EBITDA forecast 2025. The average Blueprint Medicines Corp. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
23 Blueprint Medicines Corp. Analysts have issued a net profit forecast 2025. The average Blueprint Medicines Corp. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.07 | -0.91 |
| 87.22% | 14.95% | |
| P/E | negative | |
| EV/Sales | 11.01 |
23 Analysts have issued a Blueprint Medicines Corp. forecast for earnings per share. The average Blueprint Medicines Corp. EPS is
This results in the following potential growth metrics and future valuations:
Blueprint Medicines Corp....
Current Blueprint Medicines Corp. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Wells Fargo |
Locked
➜
Locked
|
Locked | Jun 17 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Jun 05 2025 |
| UBS |
Locked
➜
Locked
|
Locked | Jun 05 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Jun 04 2025 |
| Stephens & Co. |
Locked
➜
Locked
|
Locked | Jun 03 2025 |
| JMP Securities |
Locked
➜
Locked
|
Locked | Jun 03 2025 |
| Wolfe Research |
Locked
➜
Locked
|
Locked | Jun 03 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Jun 17 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Jun 05 2025 |
|
Locked
UBS:
Locked
➜
Locked
|
Jun 05 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Jun 04 2025 |
|
Locked
Stephens & Co.:
Locked
➜
Locked
|
Jun 03 2025 |
|
Locked
JMP Securities:
Locked
➜
Locked
|
Jun 03 2025 |
|
Locked
Wolfe Research:
Locked
➜
Locked
|
Jun 03 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
